Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies

Yunseon Choi, Junwon Kim, Ikjae Lee, Jinsil Seong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background & Aims: This study was designed to reveal the prognostic significance of dose-escalated radiotherapy with tomotherapy in local control for spine metastases of primary hepatic tumours. Methods: From April 2006 to May 2012, 23 hepatocellular carcinoma patients and 7 intrahepatic cholangiocellular carcinoma patients (total 30 patients, 42 spinal lesions) were treated for metastatic spine lesions with helical tomotherapy (HT). The gross tumour volume (GTV) was defined as a tumour evident from computed tomography and magnetic resonance imaging. Median values were as follows: GTV total dose of 48 Gy (range 21-51), fraction size of 6 Gy (range 3-8) and eight fractions (range 3-17). Pain response was checked according to visual analogue scale (from 0 to 10). Results: The median follow-up was 5.6 months. Six events of local failure occurred, including five lesions in which spinal canals were involved at radiotherapy. Local control rate at 3 months was 86.6%. Biological equivalent dose (BED) was correlated with local control (AUC = 0.833). Higher BED (>56.0 Gy10) was associated with increased local control (P = 0.004). The median time to local progression in patients receiving ≤56.0 Gy10 and >56.0 Gy10 were 3 and 20.8 months respectively. Dose escalation (BED > 56.0 Gy10) was also associated with improved progression-free survival (median 14.7 vs. 2.8 months, P = 0.010). Pain reduction was observed in 90.9% (20/22) of patients with painful bone metastases. Conclusions: Dose-escalated radiotherapy (BED > 56.0 Gy10) using HT improved local control in spinal metastases of hepatic malignancies.

Original languageEnglish
Pages (from-to)462-468
Number of pages7
JournalLiver International
Volume34
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Intensity-Modulated Radiotherapy
Spine
Neoplasm Metastasis
Liver
Radiotherapy
Neoplasms
Tumor Burden
Pain
Spinal Canal
Cholangiocarcinoma
Visual Analog Scale
Disease-Free Survival
Area Under Curve
Hepatocellular Carcinoma
Tomography
Magnetic Resonance Imaging
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{6adbbc2b31e84c91aeac4fb11ecf6bbe,
title = "Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies",
abstract = "Background & Aims: This study was designed to reveal the prognostic significance of dose-escalated radiotherapy with tomotherapy in local control for spine metastases of primary hepatic tumours. Methods: From April 2006 to May 2012, 23 hepatocellular carcinoma patients and 7 intrahepatic cholangiocellular carcinoma patients (total 30 patients, 42 spinal lesions) were treated for metastatic spine lesions with helical tomotherapy (HT). The gross tumour volume (GTV) was defined as a tumour evident from computed tomography and magnetic resonance imaging. Median values were as follows: GTV total dose of 48 Gy (range 21-51), fraction size of 6 Gy (range 3-8) and eight fractions (range 3-17). Pain response was checked according to visual analogue scale (from 0 to 10). Results: The median follow-up was 5.6 months. Six events of local failure occurred, including five lesions in which spinal canals were involved at radiotherapy. Local control rate at 3 months was 86.6{\%}. Biological equivalent dose (BED) was correlated with local control (AUC = 0.833). Higher BED (>56.0 Gy10) was associated with increased local control (P = 0.004). The median time to local progression in patients receiving ≤56.0 Gy10 and >56.0 Gy10 were 3 and 20.8 months respectively. Dose escalation (BED > 56.0 Gy10) was also associated with improved progression-free survival (median 14.7 vs. 2.8 months, P = 0.010). Pain reduction was observed in 90.9{\%} (20/22) of patients with painful bone metastases. Conclusions: Dose-escalated radiotherapy (BED > 56.0 Gy10) using HT improved local control in spinal metastases of hepatic malignancies.",
author = "Yunseon Choi and Junwon Kim and Ikjae Lee and Jinsil Seong",
year = "2014",
month = "3",
day = "1",
doi = "10.1111/liv.12260",
language = "English",
volume = "34",
pages = "462--468",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "3",

}

Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. / Choi, Yunseon; Kim, Junwon; Lee, Ikjae; Seong, Jinsil.

In: Liver International, Vol. 34, No. 3, 01.03.2014, p. 462-468.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies

AU - Choi, Yunseon

AU - Kim, Junwon

AU - Lee, Ikjae

AU - Seong, Jinsil

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background & Aims: This study was designed to reveal the prognostic significance of dose-escalated radiotherapy with tomotherapy in local control for spine metastases of primary hepatic tumours. Methods: From April 2006 to May 2012, 23 hepatocellular carcinoma patients and 7 intrahepatic cholangiocellular carcinoma patients (total 30 patients, 42 spinal lesions) were treated for metastatic spine lesions with helical tomotherapy (HT). The gross tumour volume (GTV) was defined as a tumour evident from computed tomography and magnetic resonance imaging. Median values were as follows: GTV total dose of 48 Gy (range 21-51), fraction size of 6 Gy (range 3-8) and eight fractions (range 3-17). Pain response was checked according to visual analogue scale (from 0 to 10). Results: The median follow-up was 5.6 months. Six events of local failure occurred, including five lesions in which spinal canals were involved at radiotherapy. Local control rate at 3 months was 86.6%. Biological equivalent dose (BED) was correlated with local control (AUC = 0.833). Higher BED (>56.0 Gy10) was associated with increased local control (P = 0.004). The median time to local progression in patients receiving ≤56.0 Gy10 and >56.0 Gy10 were 3 and 20.8 months respectively. Dose escalation (BED > 56.0 Gy10) was also associated with improved progression-free survival (median 14.7 vs. 2.8 months, P = 0.010). Pain reduction was observed in 90.9% (20/22) of patients with painful bone metastases. Conclusions: Dose-escalated radiotherapy (BED > 56.0 Gy10) using HT improved local control in spinal metastases of hepatic malignancies.

AB - Background & Aims: This study was designed to reveal the prognostic significance of dose-escalated radiotherapy with tomotherapy in local control for spine metastases of primary hepatic tumours. Methods: From April 2006 to May 2012, 23 hepatocellular carcinoma patients and 7 intrahepatic cholangiocellular carcinoma patients (total 30 patients, 42 spinal lesions) were treated for metastatic spine lesions with helical tomotherapy (HT). The gross tumour volume (GTV) was defined as a tumour evident from computed tomography and magnetic resonance imaging. Median values were as follows: GTV total dose of 48 Gy (range 21-51), fraction size of 6 Gy (range 3-8) and eight fractions (range 3-17). Pain response was checked according to visual analogue scale (from 0 to 10). Results: The median follow-up was 5.6 months. Six events of local failure occurred, including five lesions in which spinal canals were involved at radiotherapy. Local control rate at 3 months was 86.6%. Biological equivalent dose (BED) was correlated with local control (AUC = 0.833). Higher BED (>56.0 Gy10) was associated with increased local control (P = 0.004). The median time to local progression in patients receiving ≤56.0 Gy10 and >56.0 Gy10 were 3 and 20.8 months respectively. Dose escalation (BED > 56.0 Gy10) was also associated with improved progression-free survival (median 14.7 vs. 2.8 months, P = 0.010). Pain reduction was observed in 90.9% (20/22) of patients with painful bone metastases. Conclusions: Dose-escalated radiotherapy (BED > 56.0 Gy10) using HT improved local control in spinal metastases of hepatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84893804786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893804786&partnerID=8YFLogxK

U2 - 10.1111/liv.12260

DO - 10.1111/liv.12260

M3 - Article

C2 - 23859251

AN - SCOPUS:84893804786

VL - 34

SP - 462

EP - 468

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 3

ER -